Background and Importance According to the Summary of Product Characteristics (SmPC)¹ of palivizumab, the usual regimen consists of five doses of 15 mg/kg/dose, intramuscularly, every 28 days.

For the 2022–2023 campaign, we established a novel regimen based on the Reuter et al.,² pharmacokinetic model whereby the dosage per kg decreases as the season progresses, and the initial dosage is defined based on postmenstrual age (PAGE) which is described as gestational age plus chronological age, both measured in weeks (Table 1).

Aim and Objectives To assess the effectiveness of a novel pavilizumab regimen as well as to determine the cost savings derived from the implementation of this regime.

Material and Methods Patients were classified according to their PAGE. The total dosage received per child with the novel protocol was compared with the dosage that they would have received had they been given the dosage as specified in the SmPC.

The effectiveness of the novel protocol was assessed showing no hospital admissions nor emergency department visits in patients undertaking the novel regimen.

The total expenditure on palivizumab during the 2022–2023 season was analysed comparing the expenditure on the PAGE-defined regimen to the theoretical expenditure of SPC-defined regimen.

Conclusion and Relevance The PAGE-defined regimen results in significant cost savings compared with the conventional SmPC-defined regimen.

The pharmacist’s intervention contributes to the optimisation of health resources, further increasing the sustainability of the health system.

References and/or Acknowledgements 1. https://www.ema.europa.eu/en/documents/product-information/synagis-epar-product-information_en.pdf

2. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.12364

Conflict of Interest No conflict of interest.